首页> 外文期刊>Experimental and clinical transplantation >A Case of Portal Vein Arterialization After a Liver Transplant
【24h】

A Case of Portal Vein Arterialization After a Liver Transplant

机译:一例肝移植后门静脉动脉化

获取原文
       

摘要

Hepatic artery thrombosis represents a potentially deadly complication after a liver transplant. Portal vein arterialization recently has been proposed as a bridge approach in patients with hepatic artery thrombosis needing a retransplant. We report the case of a 53-year-old man treated with a liver transplant for a cryptogenetic cirrhosis. One month after a liver transplant, a hepatic artery thrombosis was documented, and a portal vein arterialization as bridge therapy for another liver transplant was performed. After surgery, improvement in the patient's liver functioning was seen. No signs of portal hypertension or hepatic abscesses were documented. Unfortunately, 8 months after the liver transplant, the patient experienced a severe urinary infection caused by a multidrug-resistant Klebsiella and died. An increase in the oxygen supply to the liver parenchyma after portal vein arterialization represents rationale use for managing hepatic artery thromboses. Several cases of treating post-liver transplant hepatic artery thromboses have been reported in the literature. Portal vein arterialization can be used as bridge therapy in well-selected situations of post-liver transplant hepatic artery thromboses. Strict surveillance should be used to prevent the onset of complications that can exclude a patient from a transplant. The correct timing for retransplant is not fully known, but we think the shorter the time to retransplant, the better is the patient survival.
机译:肝动脉血栓形成代表肝移植后潜在的致命并发症。最近已经提出门静脉动脉化作为需要再次移植的肝动脉血栓形成患者的桥梁方法。我们报道了一名53岁男性因隐源性肝硬化接受肝移植治疗的病例。肝移植后一个月,记录了肝动脉血栓形成,并进行了门静脉动脉化作为另一种肝移植的桥梁疗法。手术后,患者的肝功能得到改善。没有记录到门脉高压或肝脓肿的迹象。不幸的是,在肝移植后8个月,患者经历了由多重耐药性克雷伯菌引起的严重尿路感染,并死亡。门静脉动脉化后肝实质中氧气供应的增加代表了用于管理肝动脉血栓形成的理论依据。文献报道了一些治疗肝移植后肝动脉血栓的病例。门静脉动脉化可以在肝移植后肝动脉血栓形成的良好选择情况下用作桥梁治疗。应采用严格的监测以防止可将患者排除在移植手术之外的并发症的发作。重新移植的正确时机尚不完全清楚,但是我们认为重新移植的时间越短,患者的生存期就越好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号